Umbilical Cord Blood-Derived Stem Cell Hair Loss Treatment Trial
Many people ask about natural hair loss remedies - treatments that will reverse baldness without the use of chemicals or surgery. However, for now at least, the only clinically-proven genetic hair loss treatments are pharmaceutical.
PRP, where the patient's blood is taken then the most plasma-dense platelets are injected back into their scalp, and food supplements containing vitamins and minerals targeted towards hair health and supporting hair growth are the closest thing to natural hair growth products. However, food supplements are not a treatment for hair loss and PRP has not been shown to be a suitable standalone treatment, though some studies have found that it may be beneficial when used in conjunction with existing topical and/or oral medications.
Whilst not the first thing that comes to mind when thinking about natural solutions, a new clinical trial will use a solution of umbilical cord blood-derived stem cells to help treat participants' genetic hair loss.
Due to take place at Dankook University Hospital in the Republic of Korea, men and women aged 18 to 54 with moderate to severe Male Pattern Baldness or mild to moderate Female Pattern Hair Loss will be recruited.
The full title of the study is: Clinical Study for the Assessment of the Hair Growth Efficacy and Safety of a Cosmetic Investigational Product, After Repeated Applications for 24 Weeks, Under Normal Conditions of Use, in the Asian Adult Subjects With Androgenic Alopecia.
Androgenic and androgenetic alopecia are the medical terms for Female and Male Pattern Hair Loss, respectively, though often one is used to represent both conditions.
Men whose hairloss is between grades III to IV on the Norwood-Hamilton scale, and women whose thinning is between grades I to II on the Ludwig-Savin scale will be invited to take part in this clinical trial. In terms of a more modern form of grading hair loss levels, participants should have a BASP classification (Basic and Specific Hair Loss) of Basic M2 to M3, or C2 to C3 or U1 to U3, or Specific V1 to V3 or F1 to F3.
Volunteers should also have hair density measuting between 60 to 160 hairs per cm2 using a photo trichogram prior to starting this treatment, with more than 5 per cent telogen hair - hair that is in the resting phase of the hair growth cycle.
Known as NGF-574H, the stem cell formulation comprising '5% conditioned media of umbilical cord blood-derived stem cells containing various trophic factors that help alleviate hair loss' will be delivered in a serum solution. A similar placebo will be given to the control group to use. Each treatment will be applied by the individual, at home, twice per day - once in the morning and once in the evening - for 24 weeks. Following this, assessments will be recorded as to each group's hair growth, hair density and hair diameter, and comparisons drawn between them.
Due to start in October 2018, the trial is aiming to have everything fully completed by November 2019.
Whilst many trials are underway to determine the 'next big thing' in hair loss treatment, it is worth considering the fact that new medications and hair growth products take a considerable amount of research and development before - if deemed safe and suitable - they are made available for use.
In cases of male and female hair loss, because these genetic conditions are permanent and progressive, waiting until a 'miracle cure' comes along may be a risky option for those wanting to reverse hairloss and prevent baldness. The reason for this is that the earlier interventional assistance begins, the better chance it has of being effective, given MHRA licensed and FDA approved or cleared treatments and therapies require the susceptible follicles to be active and capable of producing hair.
As the conditions rumble on untreated, the follicles in the areas affected by DHT - namely the vertex, the top of the scalp from crown to hairline, and temporal regions - become increasingly weak and thinning hair gets gradually finer, with more and more shedding occurring. Should true baldness develop, where the skin takes on a smooth, shiny appearance - more commonly found in men than in women - this is a sign that the follicles have been destroyed and non-surgical treatment is no longer suitable.
For this reason, anyone concerned about addressing their thinning hair or receding hairline should take expert advice in a timely manner so that they are properly informed of the options and can arrive at the best solution for them in good time. After all, should the long awaited 'miracle cure' eventually arrive, there would be nothing to stop people from switching from one to the other.
PRP, where the patient's blood is taken then the most plasma-dense platelets are injected back into their scalp, and food supplements containing vitamins and minerals targeted towards hair health and supporting hair growth are the closest thing to natural hair growth products. However, food supplements are not a treatment for hair loss and PRP has not been shown to be a suitable standalone treatment, though some studies have found that it may be beneficial when used in conjunction with existing topical and/or oral medications.
Whilst not the first thing that comes to mind when thinking about natural solutions, a new clinical trial will use a solution of umbilical cord blood-derived stem cells to help treat participants' genetic hair loss.
Hair loss serum trial
The full title of the study is: Clinical Study for the Assessment of the Hair Growth Efficacy and Safety of a Cosmetic Investigational Product, After Repeated Applications for 24 Weeks, Under Normal Conditions of Use, in the Asian Adult Subjects With Androgenic Alopecia.
Androgenic and androgenetic alopecia are the medical terms for Female and Male Pattern Hair Loss, respectively, though often one is used to represent both conditions.
Men whose hairloss is between grades III to IV on the Norwood-Hamilton scale, and women whose thinning is between grades I to II on the Ludwig-Savin scale will be invited to take part in this clinical trial. In terms of a more modern form of grading hair loss levels, participants should have a BASP classification (Basic and Specific Hair Loss) of Basic M2 to M3, or C2 to C3 or U1 to U3, or Specific V1 to V3 or F1 to F3.
Volunteers should also have hair density measuting between 60 to 160 hairs per cm2 using a photo trichogram prior to starting this treatment, with more than 5 per cent telogen hair - hair that is in the resting phase of the hair growth cycle.
Known as NGF-574H, the stem cell formulation comprising '5% conditioned media of umbilical cord blood-derived stem cells containing various trophic factors that help alleviate hair loss' will be delivered in a serum solution. A similar placebo will be given to the control group to use. Each treatment will be applied by the individual, at home, twice per day - once in the morning and once in the evening - for 24 weeks. Following this, assessments will be recorded as to each group's hair growth, hair density and hair diameter, and comparisons drawn between them.
Due to start in October 2018, the trial is aiming to have everything fully completed by November 2019.
Progressively thinning hair
Whilst many trials are underway to determine the 'next big thing' in hair loss treatment, it is worth considering the fact that new medications and hair growth products take a considerable amount of research and development before - if deemed safe and suitable - they are made available for use.
In cases of male and female hair loss, because these genetic conditions are permanent and progressive, waiting until a 'miracle cure' comes along may be a risky option for those wanting to reverse hairloss and prevent baldness. The reason for this is that the earlier interventional assistance begins, the better chance it has of being effective, given MHRA licensed and FDA approved or cleared treatments and therapies require the susceptible follicles to be active and capable of producing hair.
As the conditions rumble on untreated, the follicles in the areas affected by DHT - namely the vertex, the top of the scalp from crown to hairline, and temporal regions - become increasingly weak and thinning hair gets gradually finer, with more and more shedding occurring. Should true baldness develop, where the skin takes on a smooth, shiny appearance - more commonly found in men than in women - this is a sign that the follicles have been destroyed and non-surgical treatment is no longer suitable.
For this reason, anyone concerned about addressing their thinning hair or receding hairline should take expert advice in a timely manner so that they are properly informed of the options and can arrive at the best solution for them in good time. After all, should the long awaited 'miracle cure' eventually arrive, there would be nothing to stop people from switching from one to the other.
The Belgravia Centre
The Belgravia Centre is a world-renowned group of a hair loss clinic in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation from anywhere in the world for home-use treatment.
View our Hair Loss Success Stories, which includes the world's largest gallery of hair growth photos and demonstrates the level of success that so many of Belgravia's patients achieve.
